Patient P-01652

Synthetic patientNBL-101 · Day 120 · 35–44 · F · baseline S12Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Stable

GI state

Unstable

Inflammatory state

Improving

Nutritional resilience

Improving

Discontinuation risk

81%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S12
Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 57 GI-04 recommended — GI Support Protocol GI-04
Day 58 Patient declined — Not now
Day 59 ME-01 recommended — Monitoring Escalation ME-01
Day 60 Patient accepted — Started ME-01 in the companion
Day 63 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 47.

Primary contributors, last 14 days

GI instability-13
Nutritional resilience+7
Inflammatory activity-6
Toxicity+3

What helped?

GI Support Protocol GI-04Day 57
Declined by patient
Monitoring Escalation ME-01Day 59
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

84%

probability of meaningful tolerance improvement

284 similar trajectories
83% showed improvement
median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

60.5/100

stable · -1.5 vs previous 14 d

Toxicity

Blood

49.6/100

improving · -3.2 vs previous 14 d

Sleep quality

Wearable

39.4/100

improving · +1.8 vs previous 14 d

Energy level

Daily log

3.2/10

stable · +0.1 vs previous 14 d

Stress level

Daily log

6.8/10

improving · -0.6 vs previous 14 d

Steps

Wearable

980

improving · +326 vs previous 14 d

Adherence

Companion

46.3 %

improving · +2.4 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards restoration · 25 from the failing basin, 64 from restoration.

Would help

GI-04 GI Support Protocol
73% improved among 124 similar · onset 8 d · confidence 86%
NP-02 Dietary Support Protocol
63% improved among 64 similar · onset 10 d · confidence 71%
SC-12 Supportive Compound
76% improved among 51 similar · onset 6 d · confidence 71%

Would not help

Keep fat low
GI +5.4 next day on high-intake days · n 18
Keep histamine low
GI +4.9 next day on high-intake days · n 20
Keep alcohol low
GI +4.1 next day on high-intake days · n 17

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+5.4detractor · 95%
Histamine load
+4.9detractor · 95%
Alcohol
+4.1detractor · 95%
Spicy / capsaicin
+3.8detractor · 95%
Insoluble fibre
+0.7no signal · 19%
Simple carbohydrates
+0.3no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 61 and rising
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 28/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 56
- WearableHRV 25 ms, trending down
Autonomic recovery ↑45
- WearableResting HR 77 bpm
- Wearable980 steps/day
Drug metabolism and exposure ↑20
- BloodToxicity index 50

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 3 · butyrate capacity 28/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 18 ms
Sleep: 6.4 h
Steps: 852
Resting HR: 81 bpm

Daily log: GI score 61, nutritional resilience 44, adherence 46.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01804	19%	S19	AD-05	improved	61
P-01708	31%	S07	CR-01	improved	59
P-01835	28%	S17	CR-01	improved	56
P-01696	27%	S20	CR-01	improved	59
P-01877	27%	S01	CR-01	improved	67
P-01371	26%	S06	CR-01	improved	63
P-01388	26%	S17	CR-01	improved	59
P-01442	24%	S13	CR-01	improved	61
P-01430	20%	S05	CR-01	improved	54
P-01342	19%	S11	DT-01	improved	48
P-01767	19%	S14	DT-01	no change	63
P-01440	48%	S12	GI-04	no change	51